MITI2: Gut Microbiota-Induced Tregs for Inflammatory-Bowel-Disease (IBD) Immunotherapy
Last July 5th, we participated in the kick-off meeting in Nantes of an R&D MITI2 project led by INSERM. At Beonchip we are happy to be part of it for the next 4 years.
MITI2 focuses on the regulatory properties of a subset of microbiota-specific TR1-like regulatory T (Treg) cells. Notably, an unprecedented association between these cells and the clinical outcomes of patients in various inflammatory diseases has already been demonstrated. Therefore, this discovery holds significant potential for therapeutic use in IBD.
Existing treatments are complex, with most people requiring lifelong medications, dietary and lifestyle modifications, and some requiring surgery. In this context, the development of new therapeutic approaches appears essential. Among these approaches, immunotherapy and cell-based therapy are particularly promising strategies.
MITI2 aims to provide a pre-clinical package including i) the proof of concept that a cellular immunotherapy using the identified Tregs subset represents a treatment for IBDs and ii) the reglementary pre-clinical in vitro and in vivo toxicity.
Beonchip contribution
Within the MITI2 project, Beonchip will develop, in collaboration, a microfluidic device for the in vitro IBD model. This model is thought to allow the culture of intestine organoids that recapitulate the complexity of intestinal physiology.
MITI2 Project reference: HORIZON-HLTH-2022-DISEASE-06-02-two-stage/101080445
